Sign In
Buy PCRX
$22.32
+0.0700 (+0.315%)
At Close: Jun 03, 2026
Pacira's (PCRX) Label Expansion Study on Exparel Meets Goal
12:03pm, Thursday, 22'nd Sep 2022
Pacira's (PCRX) phase III study evaluating its marketed drug, Exparel, as a single-dose sciatic nerve block in the popliteal fossa for bunionectomy meets primary and secondary endpoints.
Pacira (PCRX) Gets Positive CHMP View on Exparel Label Expansion
07:33pm, Wednesday, 21'st Sep 2022
The CHMP gives a positive opinion on Pacira's (PCRX) marketed drug Exparel and recommended a marketing authorization for the product to treat postsurgical pain in children aged six years or older.
Pacira (PCRX) Up on Data From Exparel Label Expansion Study
12:02pm, Thursday, 08'th Sep 2022
Pacira (PCRX) reports encouraging top-line data from the phase III study evaluating Exparel as a single-dose femoral nerve block in the adductor canal for total knee arthroplasty. Shares rise.
Pacira BioSciences: Pharmaceutical Near-Term Capital-Gain Prospect
04:36am, Thursday, 11'th Aug 2022
Growing since 2016 among the healthcare industry's opioid-aversion concerns, on a multi-markets basis. Institutions hold 110% of shares, insiders only 1%.
Pacira's (PCRX) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
04:34pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Pacira's (PCRX) earnings and revenues fall shy of estimates in the second quarter of 2022.
Pacira's (PCRX) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
02:18pm, Thursday, 04'th Aug 2022
Pacira's (PCRX) earnings and revenues fall shy of estimates in the second quarter of 2022.
Pacira (PCRX) Misses Q2 Earnings and Revenue Estimates
01:15pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Pacira (PCRX) delivered earnings and revenue surprises of -37.04% and 0.06%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Pacira Biosciences Inc. (PCRX) CEO Dave Stack on Q2 2022 Results - Earnings Call Transcript
12:32pm, Wednesday, 03'rd Aug 2022
Pacira Biosciences Inc. (NASDAQ:PCRX ) Q2 2022 Results Conference Call August 3, 2022 8:30 AM ET Company Participants Susan Mesco - Head, IR Dave Stack - Chairman, CEO Charlie Reinhart - CFO Conferenc
Is a Beat in Store for BioNTech (BNTX) This Earnings Season?
03:52pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
On BioNTech's (BNTX) second-quarter earnings call, investors are expected to focus on the sales performance of its COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer.
Pacira BioSciences to Participate in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference
12:00pm, Tuesday, 02'nd Aug 2022 GlobeNewswire Inc.
TAMPA, Fla., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2022 Wedbush PacGrow Healthcare
Pacira BioSciences to Participate in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference
08:00am, Tuesday, 02'nd Aug 2022
TAMPA, Fla., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2022 Wedbush PacGrow Healthcare V
United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Q2 Release
02:01pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacira to Report Second Quarter 2022 Financial Results on Wednesday August 3, 2022
12:00pm, Wednesday, 27'th Jul 2022 GlobeNewswire Inc.
TAMPA, Fla., July 27, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on
Pacira (PCRX) Earnings Expected to Grow: What to Know Ahead of Q2 Release
02:01pm, Tuesday, 26'th Jul 2022 Zacks Investment Research
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacira BioSciences Reports Preliminary Second Quarter 2022 Revenue of $169.4 Million
11:30am, Thursday, 14'th Jul 2022 GlobeNewswire Inc.
EXPAREL average daily sales at 105% of the prior year for the second quarter and 103% of the prior year for the month of June EXPAREL average daily sales at 105% of the prior year for the second quart
